Geneva, Switzerland, 26 September 2018 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, announced that its Phase IIa study of GNbAC1 in type 1 diabetes (T1D) met the primary endpoint of safety in this new patient population. GNbAC1 is a monoclonal antibody designed to neutralize a pathogenic envelope protein, pHERV-W Env, which has been detected post mortem in about two thirds of the pancreas of patients with T1D.
More information on :
http://www.newcontact.eu/secure/media/com_newcap/files/files/GeNeuo_PR_T1D_6m_EN%281%29.pdf
